Jason Haldas, MD

Current Trials

• Phase 2 Study of Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory CD30 Positive T-cell Lymphoma

  HIC ID2000029793RoleSub InvestigatorPrimary Completion Date04/30/2028

  Recruiting Participants

  Lymphoma

• Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)

  HIC ID2000032279RoleSub InvestigatorPrimary Completion Date12/31/2033

  Recruiting Participants

  Prostate Cancer

• Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

  HIC ID2000032879RoleSub InvestigatorPrimary Completion Date12/31/2026

  Recruiting Participants

  Lung Cancer

• Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors

  HIC ID2000032098RoleSub InvestigatorPrimary Completion Date03/31/2025

  Recruiting Participants

  Pancreatic CancerThyroid and Other Endocrine Cancers

• SIMCAP (Surgery in Metastatic Carcinoma of Prostate): Phase 2.5 Multi-Institution Randomized Prospective Clinical Trial Evaluating the Impact of Cytoreductive Radical Prostatectomy Combined With Best Systemic Therapy on Oncologic and Quality of Life Outcomes in Men With Newly Diagnosed Metastatic Prostate Cancer

  HIC ID2000031290RoleSub InvestigatorPrimary Completion Date10/31/2025

  Recruiting ParticipantsGenderMaleAge18+ years

  Prostate Cancer